Active Ingredient History
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, covalent, slowly reversible β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. The combination of ceftazidime with avibactam exhibited broad-spectrum activity against Ambler class A- and class C-producing Enterobacteriaceae. AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam indicated for the treatment of patients with the following infections caused by designated susceptible microorganisms: Complicated Intra-abdominal Infections, used in combination with metronidazole and Complicated Urinary Tract Infections, including Pyelonephritis. NCATS
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Bacteremia (Phase 4)
Bacterial Infections (Phase 3)
Corneal Diseases (Phase 3)
Cystic Fibrosis (Phase 4)
Drugs, Investigational (Phase 1)
Febrile Neutropenia (Phase 2)
Gram-Negative Bacterial Infections (Phase 2)
Healthcare-Associated Pneumonia (Phase 4)
Healthy Volunteers (Phase 1)
Infections (Phase 2)
Inflammation (Phase 1)
Intestinal Neoplasms (Phase 1)
Intraabdominal Infections (Phase 4)
Kidney Diseases (Phase 1)
Neoplasms (Phase 2)
Pharmacokinetics (Phase 1)
Pneumonia, Ventilator-Associated (Phase 4)
Pyelonephritis (Phase 4)
Renal Insufficiency (Phase 1)
Safety (Phase 1)
Urinary Tract Infections (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue